Efficacy and Safety of Kabalin Cap.(Pregabalin) in Patients With Neuropathic Pain

November 9, 2026 updated by: HK inno.N Corporation

A Multi-center, Prospective, Observational Study to Evaluate Therapeutic Effectiveness and Safety of Kabalin Cap. in Patients With Neuropathic Pain

This study aims to assess the proportion of patients with peripheral or central neuropathic pain who achieve at least a 50% improvement in pain at Week 12 after receiving Kabalin Cap.(Pregabalin). The study will also evaluate changes in pain characteristics, severity, and intensity; improvement in pain-related sleep interference; and safety information collected during the study period.

Study Overview

Status

Recruiting

Detailed Description

This study will evaluate pain-related outcomes and safety in patients with peripheral or central neuropathic pain who receive Kabalin Cap.(Pregabalin). At Week 12 after treatment initiation, the proportion of patients who achieve at least a 50% improvement in pain will be assessed. Changes in pain characteristics, severity, and intensity will also be evaluated. In addition, the study will assess improvement in pain-related sleep interference and collect safety information observed during the study period.

Study Type

Observational

Enrollment (Estimated)

5217

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

University-affiliated hospitals and general hospitals where the study drug is administered

Description

Inclusion Criteria:

  1. Aged 19 years or older
  2. Patients for whom treatment with Kabalin Cap. has been selected in accordance with the approved prescribing information for peripheral or central neuropathic pain
  3. Patients who voluntarily provide written informed consent
  4. Patients who are able to complete the questionnaires

Exclusion Criteria:

  1. Patients with hypersensitivity to pregabalin or any of the excipients
  2. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  3. Pregnant or breastfeeding women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_ONLY
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of participants with a ≥50% improvement in pain severity from baseline at Week 12
Time Frame: At Week 12 after enrollment

The proportion of participants whose pain severity score, as assessed using the SF-MPQ, shows a ≥50% improvement from baseline after 12 weeks of treatment with Kabalin Cap. will be reported

At Week 12 after enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 27, 2025

Primary Completion (Estimated)

June 30, 2028

Study Completion (Estimated)

June 30, 2028

Study Registration Dates

First Submitted

November 5, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 12, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe